Deep Brain Stimulation Effects Study

Parkinson's Disease Clinical Trial

Official title:

Deep Brain Stimulation Effects: Human Proof-of-Concept Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01098565
• Other study ID #: 1654
• Status: Terminated
• Phase: Phase 1
• First received: March 25, 2010
• Last updated: August 1, 2013
• Start date: April 2010
• Est. completion date: November 2011

Study information

• Verified date: August 2013
• Source: MedtronicNeuro
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: German Institute of Medical Documentation and InformationGermany: Ethics Commission
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to provide proof-of-concept that the test product can perform as intended in an intra-operative setting and the responses to the test product are perceivable in a person. The study will also compare results of the test product to the commercially-available product.

Hypothesis: the test product will elicit successful test results in over 90% of test product.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: November 2011
• Est. primary completion date: November 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject is indicated for Activa® DBS implant for the treatment of Parkinson's disease and scheduled for surgery at the study site.

• Subject is willing to sign the informed consent to participate in the study.

• Subject is 18 years of age or older.

• Subject is a male or non-pregnant female.

• Subject has no factors that would put the subject at an additional risk for intra-operative or postoperative bleeding. This includes underlying disorders of the coagulation cascade (eg, hemophilia), disorders that affect platelet count or function (eg, Von Willebrand's disease), as well as administration of any anti-platelet or anti-coagulant medication in the 7 days prior to surgery, or any history of anticoagulant or aspirin use, that in the view of the neurosurgeon or neurologist would place the subject at an increased risk for intra-operative or postoperative bleeding.

Exclusion Criteria:

• Subject is indicated for DBS for treating a disorder other than Parkinson's disease.

• Subject has any medical contraindications to undergoing DBS surgery, (eg, infection, coagulopathy, or significant cardiac or other medical risk factors for surgery).

• Subject has a history of hemorrhagic stroke.

• Subject has a history of a neurosurgical ablation procedure.

• Subject is currently enrolled in or plans to enroll in any concurrent study that may confound the results of this study, as determined by the investigator or Medtronic.

• Subject has a diagnosis of acute myocardial infarction or cardiac arrest less than or equal to 6 months prior to the screening testing.

• Subject has a history of a seizure disorder

• Subject requires short surgery time due to general health issues, as determined by the investigator.

• Subject is a woman who is pregnant or planning to become pregnant, or a woman of child-bearing potential, who is not using a medically-acceptable method of birth control. Women of child-bearing potential must undergo a pregnancy test, with a clear negative result, no more than 7 days prior to the investigational procedure visit.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Device:
• Study device HFR0001
Study device will be tested for up to 2 hours prior to chronic device implant.

Locations

Country	Name	City	State
Germany	Christian Albrechts University of Kiel	Kiel

Sponsors (1)

Lead Sponsor	Collaborator
MedtronicNeuro

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The HFR0001 device can elicit distinct intra-operative responses in subject symptoms.	Responses include testing parameters and symptom effects	9 months	No
Secondary	Adverse events that occur with the acute implantation and intra-operative testing of the study device.	Characterization of all adverse events for all subjects from the beginning of the implant procedure through study discontinuation.	9 months.	Yes